Etanercept in Adult Dermatomyositis
Principal Investigator:
A. Amato & Muscle Study Group (9 sites)
Study Design:
Randomized, double-blind, placebo-controlled trial of Etanercept (all patients will initially be started on prednisone)
Types & Number of IIM Studied:
Active, new adult dermatomyositis (N = 30)
Entry Criteria:
Definite Dermatomyositis
IMACS Core Set Measures Included:
Physician and Patient Global Activity Assessments, Manual Muscle Testing, Health Assessment Questionnaire
Other Measures Included:
Cutaneous Assessment Disease Activity Severity Index (CDASI), pulmonary function testing, electrocardiogram, MVICT, magnetic resonance imaging, skin biopsy; DNA microarrays on muscle, skin, and peripheral white blood cells
Primary Outcome:
Cumulative dose of prednisone; Number of treatment failures; Responsiveness of IMACS outcome variables
Study Duration:
12 months
Comments:
Enrollment Completed
Contact:
-
Anthony A. Amato, M.D.
Professor of Neurology -
Brigham and Women's Hospital
Neurology, ASB 1-2
75 Francis St
Boston, MA 02115
Tel (617) 732-5436
Fax (617) 730-2885
aamato@partners.org
Return to Therapeutic Studies listing
